Bayezian Bulletin - October 2023
Hello and welcome to the second edition of the Bayezian Bulletin.
As you know, we’re passionate about utilising AI for the greater good. This newsletter aims to expand on our ultimate goal, shining a light on Bayezian in the media and any important stories you should be reading on a monthly basis.
To keep ahead of all Bayezian and AI-related news, be sure to subscribe to ensure you don’t miss the latest edition.
Bayezian in the news
Will AI take over the world?
Speaking to Maddyness , our Founder and CEO, Ed Dixon , recently shed some light on the common myths currently surrounding the development of AI. With many distorted truths spreading across the internet, it’s important to know the reality behind these assumptions and arm yourself with concrete facts.
Only then can we look to the future and start to make well-informed decisions on next steps.
With positive and negative headlines on AI published seemingly every day, it can be hard to know what to believe. Some herald AI as the solution to the world’s problems while others stress caution.
AI being exploited by criminals is a genuine concern, but it can be tackled if addressed quickly. Like it or not, its use by fraudsters also has some unexpected benefits for technological advancements, too.
Our director Glyn Heath penned his thoughts on the topic for Electronic Specifier Ltd .
Artificial intelligence is driving advances in most sectors at a remarkable rate. This is particularly true of drug discovery, where AI is revolutionising a usually drawn-out operation. But why are approval rates still falling?
It’s a timely question posed by Ed Dixon, who explores why everyone’s talking about the power of AI in drug discovery, but not actual drugs that were discovered through AI.
So, when might approvals catch up with these tech advancements?
Latest AI News
AI, and specifically regulation, is gaining plenty of traction in recent times. That’s because the European Union hopes to reach a political agreement on the Artificial Intelligence Act, or at least compromise on the main points of the draft regulation imminently.
Then, on 1st and 2nd November, British Prime Minister Rishi Sunak will welcome representatives of foreign governments and tech giants to London for an "international AI safety summit." Later in November, the G7 countries will gather for a meeting on the "Hiroshima Process," an AI discussion that began in Japan in May. With so many conversations ongoing, those in the space watch with keen interest; these decisions will have implications for many, many years to come.
Another week, another exciting medical development thanks to AI.
领英推荐
This time it’s in the realm of retinal disease detection. Researchers have created AI-Doctor, an advanced artificial intelligence system aiding in the accurate diagnosis and treatment suggestions for various Ischemic Retinal Diseases.
With detailed heat mapping, AI-Doctor has shown promising results, displaying high precision, recall, and accuracy in multiple datasets.
Get To Know: Charlotte Davidson
Through our regular Q&A, familiarise yourself with the people that make up Bayezian, what drives them and what they do when they step outside the office.
Why did you join Bayezian?
I joined Bayezian because I really like the freedom we are allowed to pursue what we are interested in, both in terms of our control over our career direction and growth as a whole but also the idea of the Plus Ones, which allow us to put forward and develop any good project ideas we may have. I also liked that we have the opportunities to work with exciting new technologies (such as large language models in my case) rather than being stuck staring at spreadsheets or otherwise just not doing what I'd like to be doing elsewhere.
What tech are you excited about right now?
The potential developments of AI in medicine, particularly how the simplification of medical language using LLMs may improve communication between experts and the public. This could be particularly helpful when dealing with stigmatised areas such as sexually transmitted infections. Additionally, tools such as First Derm (which can be used to diagnose skin issues using user-submitted images) are already starting to pop up, and have the potential to help ease the strain on overloaded medical services which is really exciting.
What inspires you?
The pace of change surrounding generative AI. Due to the constant new developments, it's a really interesting time to be in this industry. So much has changed in this space, even since I started working for Bayezian, that I wouldn't have predicted what I'm doing now when I finished my MSc a year ago. The need to be constantly learning and keeping up with new developments is great for staying inspired and avoiding stagnation.
What do you do outside of work?
I've been a swimmer all of my life, but these days I'm a frequent gym-goer and runner as well. I also love to read broadly, a pretty even mix of fiction and non-fiction, and I'm a big fan of horror films (particularly in October!).
Vacancies
ICYMI, we’re hiring. Please head to our Jobs board for more information.
What are we reading?
Here’s a quick share of the books or papers some of us are reading at the moment! A nice mixture of nerdiness and escapism, we think.
Subscribe to Crossing The T
Looking for further fascinating reading after you’ve finished the Bayezian Bulletin? We’ve got you covered. Our director Glyn Heath has launched Crossing The T, a new platform for empowering high-growth businesses with expert advice.
Blogs so far have focused on mitigating the risk of startup and scaleup failure, 15 leadership skills every entrepreneur must master and more. To read these posts in full, head to Crossing The T here.